FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Washington, D.C. 20549

11domington, 2.0. 200

OMB APP	ROVAL
OMB Number:	3235-0287
Estimated average bu	urden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

								,			1 . 7									
1. Name and Address of Reporting Person* BENNETT C FRANK					2. Issuer Name and Ticker or Trading Symbol IONIS PHARMACEUTICALS INC [IONS]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner							
(Last)	,	irst)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 01/15/2021 X Officer (give title below) below) Chief Scientific Officer											pecity			
2855 GAZELLE CT.							4 If Amendment Date of Original Filed (Menth/Date/Cont)								6. Individual or Joint/Group Filing (Check Applicable					
(Street) CARLSBAD, CA 92010					_ *.	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line) X Form filed by One Reporting Person Form filed by More than One Reporting						
(City)	(S	tate)	(Zip)			Person														
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
Date			Date	nsaction h/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4 a			Beneficia Owned F	s ally ollowing	Form:	Direct I Indirect I str. 4)	7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) or (D)	Price	Reported Transact (Instr. 3 a	ion(s)			(Instr. 4)		
Common Stock 01/				01/1	15/202	21	01/15/	2021	M ⁽¹⁾	15,520(1)) A	\$0	47,	47,996		D			
Common Stock 01/15				15/202	/2021 01/15/2021		2021	F ⁽²⁾		5,488 ⁽²⁾ D \$		\$61.2	3 42,508			D				
			Table II -								osed of, convertib			Owned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Da if any (Month/Day/	ate,	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerci Expiration Da (Month/Day/Y		ate	7. Title an of Securit Underlyin Derivative (Instr. 3 a	ies g Security	Derivative Security	9. Numbe derivative Securities Beneficial Owned Following Reported Transacti	illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership ct (Instr. 4)		
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	on(s)				
Restricted Stock Units	(3)(4)	01/15/2021	01/15/202	21	A		20,822		(5))	(5)	Common Stock	20,822	\$0.0	20,82	2	D			
Restricted Stock Units	(4)	01/15/2021	01/15/202	21	M			15,520	(5))	(5)	Common Stock	15,520	\$0.0	29,64	1	D			

Explanation of Responses:

- 1. Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.
- 2. Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
- 3. Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
- 4. Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
- 5. Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

Remarks:

/s/Patrick R. O'Neil, attorneyin-fact

01/20/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.